Company intelligence / Profile preview

InThera

Schlieren, Zurich, Switzerland

Ownership: Private
Employees: ~15
Development stage: Other

Overview

InThera is a Swiss biotechnology company focused on developing a new class of low-molecular-weight drugs to treat solid tumors. The company specializes in targeting protein-protein interactions, specifically focusing on transcription factors that are traditionally considered undruggable. Their lead programs are designed to inhibit the Signal transducer and activator of transcription 3 (STAT3) pathway, which is frequently overactivated in various cancers. By utilizing a proprietary technology platform, InThera aims to provide highly selective oral therapies for patients with limited treatment options.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on InThera.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on InThera.

Explore the full profile